top of page

Ingenta Named Finalist for Prestigious GENIAC-PRIZE, Unlocking the Power of "Failure Data" in Drug Discovery through Next-Gen AI

  • 3 days ago
  • 2 min read

Updated: 2 days ago


[TOKYO, March 24, 2026]  


Redefining R&D productivity: Ingenta’s proprietary "LLM x Graph" technology transforms tacit research knowledge into scalable organizational assets.



About the GENIAC-PRIZE The GENIAC-PRIZE is a strategic initiative by METI and NEDO designed to enhance Japan’s generative AI development capabilities and promote real-world social implementation. Official Website: https://geniac-prize.nedo.go.jp/


 Ingenta, a pioneer in specialized AI solutions, announced that it has been selected as a finalist for the GENIAC-PRIZE, a flagship national project led by Japan’s Ministry of Economy, Trade and Industry (METI) and the New Energy and Industrial Technology Development Organization (NEDO).

Out of 58 competitive applicants, Ingenta was recognized as one of only eight finalists in the "Externalization of Tacit Knowledge in Manufacturing" category. Ingenta stands as the sole finalist representing the pharmaceutical sectors, marking a significant milestone for AI implementation in deep-tech industries.

Turning "Failure" into Fuel for Innovation In collaboration with Biomimetics Sympathies, Ingenta proposed a groundbreaking system: "Autonomous Collaborative Hypothesis Formulation via Proprietary LLM x Graph Technology."




While traditional R&D often overlooks "failed" experimental data, Ingenta’s solution structures this untapped information alongside research logs and scientific literature. By integrating Large Language Models (LLMs) with Knowledge Graph technology, the system enables:

  • Preservation of Tacit Knowledge: Seamlessly capturing the intuition and expertise of veteran researchers.

  • Accelerated Hypothesis Generation: Providing AI-driven decision support to streamline the drug discovery process.

  • Scalable R&D Intelligence: Transforming fragmented data into a cohesive, searchable, and actionable asset.


"Being selected as a GENIAC-PRIZE finalist validates our vision of a future where AI doesn't just process data, but truly understands the nuances of scientific discovery," said Dennis Hsueh, CEO of Ingenta. "By capitalizing on 'failure data' that was previously discarded, we are empowering pharmaceutical leaders to reach breakthroughs faster and more reliably."

"In the high-stakes fields of drug discovery and regenerative medicine, critical insights are often hidden not just in our successes, but in the history of failed trials and complex decision-making processes," said Keisuke Onishi, CEO of Biomimetics Sympathies.

"Historically, this invaluable knowledge remained fragmented across scattered research notes, experimental logs, and individual expertise, making it nearly impossible to leverage at scale. Through our collaboration with Ingenta, we have successfully demonstrated that this disparate data can be structured into an actionable asset that directly fuels hypothesis formulation. What makes this technology truly transformative is its ability to align with the actual thought processes of researchers, going far beyond simple search or summarization. We are confident that this approach will not only revolutionize R&D in life sciences but will serve as a high-impact solution for any industry navigating complex technical documentation and trial-and-error histories."



About Ingenta Inc.

Headquartered in Tokyo, Ingenta is a deep-tech AI startup specializing in the structural transformation of technical knowledge. By leveraging its proprietary "LLM x Graph" technology, Ingenta helps R&D-intensive industries—such as pharmaceuticals and advanced manufacturing—convert vast amounts of unstructured data and tacit expertise into actionable intelligence, driving the next generation of industrial innovation.


About Biomimetics Sympathies Inc. 

Biomimetics Sympathies is a leading biotechnology firm dedicated to advancing drug discovery and regenerative medicine. By combining cutting-edge biological insights with strategic partnerships, the company focuses on developing innovative therapeutic solutions to address unmet medical needs and improve patient outcomes globally.



Contact Information

Ingenta Inc.

Mitsuyoshi Okamoto | Senior Business Development Manager



bottom of page